These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
351 related items for PubMed ID: 28934679
1. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. Wang F, Jia JS, Wang J, Zhao T, Jiang Q, Jiang H, Zhu HH. Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679 [Abstract] [Full Text] [Related]
2. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ. J Clin Oncol; 2013 Nov 20; 31(33):4215-21. PubMed ID: 24127444 [Abstract] [Full Text] [Related]
3. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Zhu HH, Guo ZP, Jia JS, Jiang Q, Jiang H, Huang XJ. Leuk Res; 2018 Feb 20; 65():14-19. PubMed ID: 29232592 [Abstract] [Full Text] [Related]
4. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Jiang H, Liang GW, Huang XJ, Jiang Q, Han S, Shi LW, Zhu HH. Leuk Res; 2015 Dec 20; 39(12):1319-24. PubMed ID: 26403986 [Abstract] [Full Text] [Related]
5. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ. Lancet Oncol; 2018 Jul 20; 19(7):871-879. PubMed ID: 29884593 [Abstract] [Full Text] [Related]
6. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. J Clin Oncol; 2017 Feb 20; 35(6):605-612. PubMed ID: 27400939 [Abstract] [Full Text] [Related]
7. Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide. Cingelova S, Mikuskova E, Demitrovicova L, Mikudova V, Slobodova A, Spanikova J, Vasickova R, Urban D, Drgona L, Oravcova I. Leuk Res; 2024 Oct 20; 145():107567. PubMed ID: 39197329 [Abstract] [Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X, Zhang H, Chen L, Wang M, Xi J, Liu X, Xie M, Li D, Gulati ES, Gong S, Wang H. Trials; 2018 Sep 05; 19(1):476. PubMed ID: 30185214 [Abstract] [Full Text] [Related]
9. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Blood; 2006 May 01; 107(9):3469-73. PubMed ID: 16373661 [Abstract] [Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D, UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Lancet Oncol; 2015 Oct 01; 16(13):1295-305. PubMed ID: 26384238 [Abstract] [Full Text] [Related]
11. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z. Int J Hematol; 1999 Dec 01; 70(4):248-60. PubMed ID: 10643151 [Abstract] [Full Text] [Related]
12. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia. Luo JS, Zhang XL, Huang DP, Chen YQ, Wan WQ, Mai HR, Chen HQ, Wen H, Liu RY, Chen GH, Li Y, Luo XQ, Tang YL, Huang LB. Ann Hematol; 2023 Jul 01; 102(7):1713-1721. PubMed ID: 37199788 [Abstract] [Full Text] [Related]
16. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia. Lou Y, Tong H, Yu W, Wei J, Xu W, Mao L, Jin J. Leuk Res; 2019 Aug 01; 83():106168. PubMed ID: 31202077 [Abstract] [Full Text] [Related]
17. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. Jin B, Hou KZ, Liu YP, Yu P. Chin Med Sci J; 2006 Sep 01; 21(3):171-4. PubMed ID: 17086739 [Abstract] [Full Text] [Related]
18. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN, Chen JP, Liu JP, Xia Y. Zhong Xi Yi Jie He Xue Bao; 2009 Nov 01; 7(11):1024-34. PubMed ID: 19912733 [Abstract] [Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J. Hematol Oncol; 2014 Mar 01; 32(1):40-6. PubMed ID: 23963734 [Abstract] [Full Text] [Related]